^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MVI-816

    i
    Associations
    News

    Trials

    Company:
    Madison Vaccines
    Drug class:
    Immunostimulant, Prostatic acid phosphatase inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer (NCT02499835)
    Phase 1/2
    University of Wisconsin, Madison
    Completed
    Last update posted :
    08/01/2023
    Initiation :
    07/01/2015
    Primary completion :
    08/09/2021
    Completion :
    07/27/2023
    PD-L1 • PD-1
    |
    PD-L1 expression • PD-1 expression
    |
    Keytruda (pembrolizumab) • MVI-816
    Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer (NCT01706458)
    Phase 2
    University of Wisconsin, Madison
    Completed
    Last update posted :
    06/18/2021
    Initiation :
    05/20/2013
    Primary completion :
    06/12/2017
    Completion :
    08/13/2020
    CSF2 • GZMB
    |
    Provenge (sipuleucel-T) • MVI-816
    Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer (NCT00849121)
    Phase 2
    University of Wisconsin, Madison
    Completed
    Last update posted :
    11/21/2019
    Initiation :
    03/16/2009
    Primary completion :
    02/17/2014
    Completion :
    02/17/2014
    CSF2
    |
    MVI-816
    Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer (NCT00582140)
    Phase 1
    University of Wisconsin, Madison
    Completed
    Last update posted :
    11/19/2019
    Initiation :
    03/01/2005
    Primary completion :
    08/01/2008
    Completion :
    08/01/2008
    CD8 • IFNG • CSF2
    |
    MVI-816